Navigation Links
US Oncology Launches Oncology-Specific EHR to the Open Market
Date:6/10/2009

iKnowMed now available to community-based oncology practices

HOUSTON, June 10 /PRNewswire/ -- Today US Oncology, Inc., supporting the nation's foremost cancer treatment and research network and working with physicians, manufacturers and payers to advance cancer care in America, announces the launch of iKnowMed(TM) to the open market. iKnowMed is an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists.

Developed in 1996, US Oncology acquired iKnowMed in 2004. The comprehensive collaboration between the oncology physicians since the acquisition has led to a technology excellence that is completely focused on the needs of community oncologists and their patients.

Today's iKnowMed goes beyond delivering standard EHR features by leveraging technology that helps physicians focus on clinical excellence and cost effectiveness in community cancer care. iKnowMed facilitates access to powerful new solutions such as US Oncology's Innovent Oncology program, which provides Level I evidence-based medicine pathways to help oncologists realize the benefits of pay-for-performance. For practices participating in the US Oncology Research network, iKnowMed can match patients to appropriate clinical trials, increasing access to the latest treatment opportunities across the nation.

Other features of iKnowMed include oncology-specific terminology, decision support, outcomes reporting, imaging reports, comprehensive patient history, comprehensive cancer regimen library, dictation and transcription, lab results, detailed cancer diagnosis and staging content, and practice efficiencies.

"As America's healthcare system moves toward a pay-for-performance environment, in which higher-performing doctors receive preferred compensation, it is essential that oncology practices accurately document and report outcomes while achieving greater efficiency," says Cindy Chavez, vice president of iKnowMed. "iKnowMed provides solutions that will help drive this clinical excellence."

"We're excited about the opportunity to offer our electronic health record system to the open market," says Bruce Broussard, president and CEO of US Oncology. "With the recent signing of the American Recovery and Reinvestment Act, which offers incentives to physicians for the meaningful use of health technology, we are proud to offer oncologists an EHR solution that is specifically designed to meet their needs."

iKnowMed provides physicians with online access to patient records 24 hours a day, 7 days a week. This allows treatment decisions to be made from anywhere at any time, without the need of a hardcopy patient record. Patient safety is enhanced by eliminating handwritten notes and orders, minimizing misinterpretations, and the system detects possible medication conflicts, generating a safety alert to the attending oncologist and staff. The system also helps practices stay current on billing as charge codes, billable units, primary diagnosis codes and billable drug waste for each visit are calculated, allowing staff to spend more time focusing on patient care.

Community oncologists across the nation are invited to attend a special webinar focusing on the Medicare Health Information Technology (HIT) Stimulus at 2 pm EDT, Friday, July 10. Sponsored by iKnowMed, this webinar will feature a status report of standards for qualified EHRs and meaningful use requirements -- as defined by the Office of the National Coordinator for Health Information Technology (ONCHIT) at the Secretariat of Health & Human Services (HHS) -- how standards should be set, and which standards should apply to oncology-specific EHRs. To register for the webinar, visit www.opspharmacist.com/HITStimulus. For more information on iKnowMed or other US Oncology services, call (866) 216-5053 or visit www.usoncology.com.

About US Oncology

US Oncology, Inc., headquartered in the Houston area, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,227 physicians operating in 468 locations, including 95 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aptium Oncology Names New Chief Operating Officer
2. New Debt Securities of US Oncology, Inc.
3. Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer
4. US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering
5. Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
6. MedTrust Online Completes Second Round of Financing, Releases Next Generation Search Engine for Oncology Utilizing Dell eHealthcare Architecture Framework
7. Tool Shows Promise for Measuring Productivity of Mid-Level Oncology Providers
8. PRA International Oncology Experts at ASCO
9. Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle
10. Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology
11. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... HEIGHTS, MICHIGAN (PRWEB) , ... February 22, 2017 ... ... and analysis of issues related to spine practices, is featuring Michigan neurosurgeon Jay ... is known as one of a small number of neurosurgeons in Michigan performing ...
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a micronutrient found ... heart-protective benefit from eating soy foods, while others do not, a University of Pittsburgh ... to produce equol—a substance made by some types of “good” gut bacteria when they ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of ... report that family members or friends have also commented about their poor hearing. ... wear hearing aids. One reason, suggested by 89 percent of American respondents, is ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens Home ... Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of 2016, ... booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood at ...
(Date:2/22/2017)... Troy, NY (PRWEB) , ... February 22, 2017 , ... ... effort — especially for hospitals and health systems. Smith & Jones’ delves into this ... In this episode, President of Smith & Jones David Vener meets up with social ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... -- Bioness, Inc., the leading provider of cutting edge, clinically ... successful StimRouter Neuromodulation System implantations in Europe ... Netherlands ), South Victoria ... Kliniek Park Leopold Chirec ( Brussels, Belgium ... further support clinicians across the continent who are looking ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology: